Erstellt von fchar99
Moleculin Biotech Inc diskutieren
Moleculin Biotech Inc
WKN: A2QQM0 / Symbol: MBRX / Name: Moleculin Biotech / Aktie / Pharmazeutika / Micro Cap /
0,41 €
1,53 %
fchar99 stimmt der Buy-Einschätzung von melinda zu
fchar99 stimmt am 11.07.2017 der Buy-Einschätzung von melinda mit dem Kursziel 2.0$ zu.Überschrift: cancer pancreas
(Zielkurs erreicht)
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $16.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Neueste Beiträge
Royal_Bank_of_Canada in Discuss Verrica Pharmaceuticals